跳至主要内容
临床试验/NCT04542980
NCT04542980已完成不适用

Qualitative Evaluation of Tear Fluid and Blood for IgM and IgG Produced in Response to SARS-CoV2, the Virus Responsible for COVID-19.

Namida Lab1 个研究点 分布在 1 个国家目标入组 44 人开始时间: 2020年9月15日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
44
试验地点
1
主要终点
Qualitative assessment of IgM and/or IgG by indirect ELISA assay.

研究概览

简要总结

This study objective is to collect tear and blood samples from individuals with positive SARS-COV2 diagnosis and test those samples for the presence of various SARS-COV2 viral antigens and autoantibodies.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 100 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 18 years of age or older Has been tested for SARS-CoV2 and awaiting results Sample collection for SARS-CoV2 testing Tested positive for SARS-CoV2 virus (confirmed by RT-PCR) prior to enrollment

排除标准

  • Under 18 years of age Concurrent eye infection or trauma unrelated to presence of SARS-CoV2 virus. Advanced COVID-19 state what would preclude safe and feasible sample collection.

结局指标

主要结局

Qualitative assessment of IgM and/or IgG by indirect ELISA assay.

时间窗: through study completion, up to 8 months

Determination of the presence or absence of IgM and/or IgG autoantibodies in response to SARS-CoV2 infection. In the case of presence, concentration may be determined as well.

次要结局

未报告次要终点

研究者

发起方
Namida Lab
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验